These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 26876216)

  • 21. Paracrine HGF/c-MET enhances the stem cell-like potential and glycolysis of pancreatic cancer cells via activation of YAP/HIF-1α.
    Yan B; Jiang Z; Cheng L; Chen K; Zhou C; Sun L; Qian W; Li J; Cao J; Xu Q; Ma Q; Lei J
    Exp Cell Res; 2018 Oct; 371(1):63-71. PubMed ID: 30056064
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Co-targeting of Cyclooxygenase-2 and FoxM1 is a viable strategy in inducing anticancer effects in colorectal cancer cells.
    Ahmed M; Hussain AR; Siraj AK; Uddin S; Al-Sanea N; Al-Dayel F; Al-Assiri M; Beg S; Al-Kuraya KS
    Mol Cancer; 2015 Jul; 14():131. PubMed ID: 26159723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells.
    Qian LW; Mizumoto K; Inadome N; Nagai E; Sato N; Matsumoto K; Nakamura T; Tanaka M
    Int J Cancer; 2003 May; 104(5):542-9. PubMed ID: 12594808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody.
    Farrell PJ; Matuszkiewicz J; Balakrishna D; Pandya S; Hixon MS; Kamran R; Chu S; Lawson JD; Okada K; Hori A; Mizutani A; Iwata H; de Jong R; Hibner B; Vincent P
    Mol Cancer Ther; 2017 Jul; 16(7):1269-1278. PubMed ID: 28341789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic and expression analysis of MET, MACC1, and HGF in metastatic colorectal cancer: response to met inhibition in patient xenografts and pathologic correlations.
    Galimi F; Torti D; Sassi F; Isella C; Corà D; Gastaldi S; Ribero D; Muratore A; Massucco P; Siatis D; Paraluppi G; Gonella F; Maione F; Pisacane A; David E; Torchio B; Risio M; Salizzoni M; Capussotti L; Perera T; Medico E; Di Renzo MF; Comoglio PM; Trusolino L; Bertotti A
    Clin Cancer Res; 2011 May; 17(10):3146-56. PubMed ID: 21447729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SOX9 in prostate cancer is upregulated by cancer-associated fibroblasts to promote tumor progression through HGF/c-Met-FRA1 signaling.
    Qin H; Yang Y; Jiang B; Pan C; Chen W; Diao W; Ding M; Cao W; Zhang Z; Chen M; Gao J; Zhao X; Qiu X; Guo H
    FEBS J; 2021 Sep; 288(18):5406-5429. PubMed ID: 33705609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatocyte growth factor sensitizes brain tumors to c-MET kinase inhibition.
    Zhang Y; Farenholtz KE; Yang Y; Guessous F; Dipierro CG; Calvert VS; Deng J; Schiff D; Xin W; Lee JK; Purow B; Christensen J; Petricoin E; Abounader R
    Clin Cancer Res; 2013 Mar; 19(6):1433-44. PubMed ID: 23386689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.
    Slørdahl TS; Denayer T; Moen SH; Standal T; Børset M; Ververken C; Rø TB
    Eur J Haematol; 2013 Nov; 91(5):399-410. PubMed ID: 23952536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.
    Hov H; Holt RU; Rø TB; Fagerli UM; Hjorth-Hansen H; Baykov V; Christensen JG; Waage A; Sundan A; Børset M
    Clin Cancer Res; 2004 Oct; 10(19):6686-94. PubMed ID: 15475459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
    Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S
    Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling.
    Owusu BY; Bansal N; Venukadasula PK; Ross LJ; Messick TE; Goel S; Galemmo RA; Klampfer L
    Oncotarget; 2016 May; 7(20):29492-506. PubMed ID: 27121052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FOXM1 promotes the warburg effect and pancreatic cancer progression via transactivation of LDHA expression.
    Cui J; Shi M; Xie D; Wei D; Jia Z; Zheng S; Gao Y; Huang S; Xie K
    Clin Cancer Res; 2014 May; 20(10):2595-606. PubMed ID: 24634381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. USP22 promotes the G1/S phase transition by upregulating FoxM1 expression via β-catenin nuclear localization and is associated with poor prognosis in stage II pancreatic ductal adenocarcinoma.
    Ning Z; Wang A; Liang J; Xie Y; Liu J; Feng L; Yan Q; Wang Z
    Int J Oncol; 2014 Oct; 45(4):1594-608. PubMed ID: 24993031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation between HGF/c-Met and Notch1 signaling pathways in human gastric cancer cells.
    Huang KH; Sung IC; Fang WL; Chi CW; Yeh TS; Lee HC; Yin PH; Li AF; Wu CW; Shyr YM; Yang MH
    Oncol Rep; 2018 Jul; 40(1):294-302. PubMed ID: 29781036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10.
    Xie T; Geng J; Wang Y; Wang L; Huang M; Chen J; Zhang K; Xue L; Liu X; Mao X; Chen Y; Wang Q; Dai T; Ren L; Yu H; Wang R; Chen L; Chen C; Chu X
    Oncotarget; 2017 Jan; 8(5):8574-8589. PubMed ID: 28051999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FOXC2 promotes colorectal cancer metastasis by directly targeting MET.
    Cui YM; Jiao HL; Ye YP; Chen CM; Wang JX; Tang N; Li TT; Lin J; Qi L; Wu P; Wang SY; He MR; Liang L; Bian XW; Liao WT; Ding YQ
    Oncogene; 2015 Aug; 34(33):4379-90. PubMed ID: 25381815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hepatocyte growth factor-mediated cell invasion in pancreatic cancer cells is dependent on neuropilin-1.
    Matsushita A; Götze T; Korc M
    Cancer Res; 2007 Nov; 67(21):10309-16. PubMed ID: 17974973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor-stromal cell interaction under hypoxia increases the invasiveness of pancreatic cancer cells through the hepatocyte growth factor/c-Met pathway.
    Ide T; Kitajima Y; Miyoshi A; Ohtsuka T; Mitsuno M; Ohtaka K; Koga Y; Miyazaki K
    Int J Cancer; 2006 Dec; 119(12):2750-9. PubMed ID: 16998831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Green tea (-)-epigallocatechin-3-gallate inhibits HGF-induced progression in oral cavity cancer through suppression of HGF/c-Met.
    Koh YW; Choi EC; Kang SU; Hwang HS; Lee MH; Pyun J; Park R; Lee Y; Kim CH
    J Nutr Biochem; 2011 Nov; 22(11):1074-83. PubMed ID: 21292466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways.
    Wu SQ; Huang SH; Lin QW; Tang YX; Huang L; Xu YG; Wang SP
    Pharmacol Res; 2022 Jan; 175():106040. PubMed ID: 34954029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.